HONG KONG – In a deal involving up to $391.5 million, HKEX-listed Innovent Biologics Inc. (HKG:1801) in-licensed three clinical-stage assets from Incyte Corp. to develop and commercialize them in the Chinese mainland, Hong Kong, Macau and Taiwan.